These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12713795)

  • 1. CR2 units of CR2 complexes are possibly associated with nucleophilic agents through reactive covalent links.
    Di Certo MG; Faggioni A; Barile G
    Cell Biol Int; 2003; 27(1):7-22. PubMed ID: 12713795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules.
    Molina H; Perkins SJ; Guthridge J; Gorka J; Kinoshita T; Holers VM
    J Immunol; 1995 May; 154(10):5426-35. PubMed ID: 7730644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21).
    Hannan JP
    Curr Protein Pept Sci; 2016; 17(5):463-87. PubMed ID: 26916158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site.
    Myones BL; Ross GD
    Complement; 1987; 4(2):87-98. PubMed ID: 3497773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
    Diefenbach RJ; Isenman DE
    J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
    Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
    Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The solvent at antigen-binding site regulated C3d-CR2 interactions through the C-terminal tail of C3d at different ion strengths: insights from molecular dynamics simulation.
    Zhang Y; Guo J; Li L; Liu X; Yao X; Liu H
    Biochim Biophys Acta; 2016 Oct; 1860(10):2220-31. PubMed ID: 27154286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for three binding sites for C3 (hemolytically inactive), C3b and C3d on a CR2-positive Burkitt lymphoma-derived cell line (Raji).
    Barile G; Di Renzo L; Lipari M; Frati L; Faggioni A
    FEBS Lett; 1993 Jun; 324(3):319-24. PubMed ID: 8405374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L; Isenman DE
    J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21).
    Prodinger WM; Schwendinger MG; Schoch J; Köchle M; Larcher C; Dierich MP
    J Immunol; 1998 Nov; 161(9):4604-10. PubMed ID: 9794388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus/complement fragment C3d receptor (CR2) reacts with p53, a cellular antioncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2 antibodies.
    Barel M; Fiandino A; Lyamani F; Frade R
    Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10054-8. PubMed ID: 2557614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligands of CR2 do not interfere with C3 fragment fixation or enhanced NK sensitivity of Raji cells treated with human serum.
    Yefenof E; Ramos OF; Nilsson B; Klein E
    Immunol Lett; 1989 Jun; 21(4):303-6. PubMed ID: 2527817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Events related to Epstein-Barr virus binding and superinfection of Raji cells.
    Barile G; Di Certo MG; Cirone M; Frati L; Pontieri GM; Faggioni A; Di Renzo L
    Intervirology; 1994; 37(5):245-51. PubMed ID: 7698879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses.
    Qin D; Wu J; Carroll MC; Burton GF; Szakal AK; Tew JG
    J Immunol; 1998 Nov; 161(9):4549-54. PubMed ID: 9794381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
    Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
    J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
    Olesen EH; Johnson AA; Damgaard G; Leslie RG
    Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells.
    Nielsen CH; Pedersen ML; Marquart HV; Prodinger WM; Leslie RG
    Eur J Immunol; 2002 May; 32(5):1359-67. PubMed ID: 11981823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement factors H and I synthesized by B cell lines function to generate a growth factor activity from C3.
    Vĕtvicka V; Reed W; Hoover ML; Ross GD
    J Immunol; 1993 May; 150(9):4052-60. PubMed ID: 8473749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cell complement receptor 2 transfer reaction.
    Lindorfer MA; Jinivizian HB; Foley PL; Kennedy AD; Solga MD; Taylor RP
    J Immunol; 2003 Apr; 170(7):3671-8. PubMed ID: 12646632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.